JP2006519852A - 弱塩基の塩 - Google Patents

弱塩基の塩 Download PDF

Info

Publication number
JP2006519852A
JP2006519852A JP2006507175A JP2006507175A JP2006519852A JP 2006519852 A JP2006519852 A JP 2006519852A JP 2006507175 A JP2006507175 A JP 2006507175A JP 2006507175 A JP2006507175 A JP 2006507175A JP 2006519852 A JP2006519852 A JP 2006519852A
Authority
JP
Japan
Prior art keywords
salt
pharmaceutical composition
carbon atoms
composition according
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006507175A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006519852A5 (https=
Inventor
サミュエル エイチ． ヤルコースキー，
タパン サングビ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Arizona
Original Assignee
University of Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/402,347 external-priority patent/US7022712B2/en
Application filed by University of Arizona filed Critical University of Arizona
Publication of JP2006519852A publication Critical patent/JP2006519852A/ja
Publication of JP2006519852A5 publication Critical patent/JP2006519852A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2006507175A 2003-03-12 2004-03-12 弱塩基の塩 Pending JP2006519852A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US45403503P 2003-03-12 2003-03-12
US45451403P 2003-03-13 2003-03-13
US10/402,347 US7022712B2 (en) 2002-03-26 2003-03-26 Solubilization of weak bases
PCT/US2004/007786 WO2004081006A1 (en) 2003-03-12 2004-03-12 Weak base salts

Publications (2)

Publication Number Publication Date
JP2006519852A true JP2006519852A (ja) 2006-08-31
JP2006519852A5 JP2006519852A5 (https=) 2007-04-19

Family

ID=32995897

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006507175A Pending JP2006519852A (ja) 2003-03-12 2004-03-12 弱塩基の塩

Country Status (6)

Country Link
EP (1) EP1606290A1 (https=)
JP (1) JP2006519852A (https=)
AU (1) AU2004220053A1 (https=)
CA (1) CA2515289A1 (https=)
MX (1) MXPA05009564A (https=)
WO (1) WO2004081006A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015231990A (ja) * 2008-11-19 2015-12-24 セファロン、インク． インダゾロ［５，４−ａ］ピロロ［３，４−ｃ］カルバゾール化合物の新しい形態

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
KR101452915B1 (ko) 2006-05-04 2014-10-21 베링거 인겔하임 인터내셔날 게엠베하 다형태
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
CA2736421A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CA3070513C (en) 2010-05-05 2023-01-03 Boehringer Ingelheim International Gmbh A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis
KR20130093012A (ko) 2010-06-24 2013-08-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
DK2731947T3 (en) 2011-07-15 2019-04-23 Boehringer Ingelheim Int SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1195180A (en) * 1967-05-05 1970-06-17 Du Pont Use of Alkyl 2-Benzimidazole-Carbamate Salts a Fungicides
GB1391873A (en) * 1972-05-17 1975-04-23 Canadian Patents Dev Method for the treatment of trees subject to dutch elm disease and other fungus diseases
JPS5459338A (en) * 1977-10-20 1979-05-12 Takeda Chem Ind Ltd Remedy for dermatomycosis
DE3602881A1 (de) * 1985-02-04 1986-08-07 Chinoin Gyógyszer és Vegyészeti Termékek Gyára RT., Budapest Neue fungizid wirkende salze, verfahren zu deren herstellung und diese verbindungen enthaltende agrochemische praeparate
JP2003506482A (ja) * 1999-08-13 2003-02-18 ザ プロクター アンド ギャンブル カンパニー 癌の治療法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1195180A (en) * 1967-05-05 1970-06-17 Du Pont Use of Alkyl 2-Benzimidazole-Carbamate Salts a Fungicides
GB1391873A (en) * 1972-05-17 1975-04-23 Canadian Patents Dev Method for the treatment of trees subject to dutch elm disease and other fungus diseases
JPS5459338A (en) * 1977-10-20 1979-05-12 Takeda Chem Ind Ltd Remedy for dermatomycosis
DE3602881A1 (de) * 1985-02-04 1986-08-07 Chinoin Gyógyszer és Vegyészeti Termékek Gyára RT., Budapest Neue fungizid wirkende salze, verfahren zu deren herstellung und diese verbindungen enthaltende agrochemische praeparate
JP2003506482A (ja) * 1999-08-13 2003-02-18 ザ プロクター アンド ギャンブル カンパニー 癌の治療法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015231990A (ja) * 2008-11-19 2015-12-24 セファロン、インク． インダゾロ［５，４−ａ］ピロロ［３，４−ｃ］カルバゾール化合物の新しい形態
JP2018008977A (ja) * 2008-11-19 2018-01-18 セファロン、インク． インダゾロ［５，４−ａ］ピロロ［３，４−ｃ］カルバゾール化合物の新しい形態

Also Published As

Publication number Publication date
EP1606290A1 (en) 2005-12-21
MXPA05009564A (es) 2005-11-17
AU2004220053A1 (en) 2004-09-23
CA2515289A1 (en) 2004-09-23
WO2004081006A1 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
JP2006519852A (ja) 弱塩基の塩
US10519176B2 (en) Crystalline forms
Zhang et al. The comparative study of cocrystal/salt in simultaneously improving solubility and permeability of acetazolamide
Liu et al. Pharmaceutical salts/cocrystals of enoxacin with dicarboxylic acids: Enhancing in vitro antibacterial activity of enoxacin by improving the solubility and permeability
JP2020100624A (ja) Ｌ−オルニチンフェニルアセテートおよびその製造方法
US6242460B1 (en) Zolpidem salt forms
BRPI0818464B1 (pt) método para preparar maleato de (e)-n-{4-[3-cloro-4-(2-piridinilmetóxi)anilina]-3-ciano-7-etóxi-6-quinolinil}-4-(dimetilamino)-2-butenamida sob a forma de um monoidrato cristalino
WO1992015332A1 (en) Novel salts/ion pairs of non-steroidal anti-inflammatory drugs in various dosage forms
Khatioda et al. Solubility and in vitro drug permeation behavior of ethenzamide cocrystals regulated in physiological pH environments
PL184885B1 (pl) Monohydrat┴chlorowodorku┴kwasu┴1-cyklopropylo-7-([SĆS]-2Ć8-diazabicyklo-[4.3.0]-non-8-ylo)-6-fluoro-1Ć4-dihydro-8-metoksy-4-okso-3-chinolinokarboksylowegoĆ┴zwanego┴CDCHĆ┴sposób┴wytwarzania┴monohydratu┴CDCH┴i┴środek┴farmaceutyczny┴zawierający┴monohydrat┴CDCH
JP5405311B2 (ja) ｍＧｌｕＲ５受容体アンタゴニストの多形
ES2975319T3 (es) Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción
Diniz et al. Structural aspects, solid-state properties, and solubility performance of pharmaceutical sertraline-based organic salts
Mannava et al. Solubility and permeability enhancement of BCS class IV drug ribociclib through cocrystallization
US20070043070A1 (en) Weak base salts
EP4198016A1 (en) Nimesulide salts and method of obtaining nimesulide salt crystals
Chi et al. Sodium salts and solvate of rebamipide: Synthesis, structure, and pharmacokinetic study
An et al. Exploring the differences in crystal structure landscapes and physicochemical properties of enrofloxacin through the number of-OH in coformers: A case study
EP3430018B1 (en) Crystal form comprising lithium ions, pharmaceutical compositions thereof, methods for preparation and their uses for the treatment of depressive disease
KR20210008829A (ko) 디히드로피리미딘 화합물의 고체 형태 및 이의 제조 방법 및 이의 용도
WO2010019398A1 (en) Two phase bioactive formulations
JPWO2002083633A1 (ja) トシル酸スプラタスト結晶
CN103841828B (zh) 德尼布林二盐酸盐
JP2023531077A (ja) 化合物の塩、及び塩を含む医薬組成物
Wang et al. Study on Novel Solid-State Forms of Sorafenib with Advantages in Terms of Solubility

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100817

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110131